User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Cancer DNA vaccines: current preclinical and clinical developments and future perspectives.

Primary tabs

Lopes, Alessandra [UCL] Vandermeulen, Gaëlle [UCL] Préat, Véronique [UCL]

The recent developments in immuno-oncology have opened an unprecedented avenue for the emergence of vaccine strategies. Therapeutic DNA cancer vaccines are now considered a very promising strategy to activate the immune system against cancer. In the past, several clinical trials using plasmid DNA vaccines demonstrated a good safety profile and the activation of a broad and specific immune response. However, these vaccines often demonstrated only modest therapeutic effects in clinical trials due to the immunosuppressive mechanisms developed by the tumor. To enhance the vaccine-induced immune response and the treatment efficacy, DNA vaccines could be improved by using two different strategies. The first is to increase their immunogenicity by selecting and optimizing the best antigen(s) to be inserted into the plasmid DNA. The second strategy is to combine DNA vaccines with other complementary therapies that could improve their activity by attenuating immunosuppression in the tumor microenvironment or by increasing the activity/number of immune cells. A growing number of preclinical and clinical studies are adopting these two strategies to better exploit the potential of DNA vaccination. In this review, we analyze the last 5-year preclinical studies and 10-year clinical trials using plasmid DNA vaccines for cancer therapy. We also investigate the strategies that are being developed to overcome the limitations in cancer DNA vaccination, revisiting the rationale for different combinations of therapy and the different possibilities in antigen choice. Finally, we highlight the most promising developments and critical points that need to be addressed to move towards the approval of therapeutic cancer DNA vaccines as part of the standard of cancer care in the future.

Document type Article de périodique (Journal article) – Article de recherche
Publication date 2019
Language Anglais
Journal information "Journal of experimental & clinical cancer research : CR" - Vol. 38, no.1, p. 146 (2019)
Peer reviewed yes
e-issn 1756-9966
Publication status Publié
Affiliation UCL - SSS/LDRI - Louvain Drug Research Institute
Keywords Antigens ; Cancer ; Cancer vaccines ; Combination therapy ; DNA vaccines ; Immuno-oncology ; Immunotherapy ; Neoantigens
Links
  1. Tiptiri-Kourpeti Angeliki, Spyridopoulou Katerina, Pappa Aglaia, Chlichlia Katerina, DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy, 10.1016/j.pharmthera.2016.05.004
  2. Gasser M, Waaga-Gasser AM. Therapeutic antibodies in Cancer therapy. In: Böldicke T, editor. Protein targeting compounds: prediction, selection and activity of specific inhibitors. Cham: Springer International Publishing; 2016. p. 95–120.
  3. Clarke Jeffrey M., George Daniel J., Lisi Stacey, Salama April K. S., Immune Checkpoint Blockade: The New Frontier in Cancer Treatment, 10.1007/s11523-017-0549-7
  4. Hargadon Kristian M., Johnson Coleman E., Williams Corey J., Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors, 10.1016/j.intimp.2018.06.001
  5. Fry T. J., Mackall C. L., T-cell adoptive immunotherapy for acute lymphoblastic leukemia, 10.1182/asheducation-2013.1.348
  6. Schlom J., Therapeutic Cancer Vaccines: Current Status and Moving Forward, 10.1093/jnci/djs033
  7. Gatti-Mays Margaret E., Redman Jason M., Collins Julie M., Bilusic Marijo, Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations, 10.1080/21645515.2017.1364322
  8. Cebon Jonathan, Perspective: cancer vaccines in the era of immune checkpoint blockade, 10.1007/s00335-018-9786-z
  9. Amara Suneetha, Tiriveedhi Venkataswarup, The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy, 10.3390/ijms18030650
  10. Coulie Pierre G., Van den Eynde Benoît J., van der Bruggen Pierre, Boon Thierry, Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy, 10.1038/nrc3670
  11. Boon T., Human tumor antigens recognized by T lymphocytes, 10.1084/jem.183.3.725
  12. Finn Olivera J., Human Tumor Antigens Yesterday, Today, and Tomorrow, 10.1158/2326-6066.cir-17-0112
  13. Strioga Marius M., Darinskas Adas, Pasukoniene Vita, Mlynska Agata, Ostapenko Valerijus, Schijns Virgil, Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: To use or not to use?, 10.1016/j.vaccine.2014.05.006
  14. Li L, Goedegebuure S P, Gillanders W E, Preclinical and clinical development of neoantigen vaccines, 10.1093/annonc/mdx681
  15. Alibek Kenneth, Baiken Yeldar, Kakpenova Ainur, Mussabekova Assel, Zhussupbekova Samal, Akan Madina, Sultankulov Bolat, Implication of human herpesviruses in oncogenesis through immune evasion and supression, 10.1186/1750-9378-9-3
  16. Martin-Liberal Juan, Ochoa de Olza María, Hierro Cinta, Gros Alena, Rodon Jordi, Tabernero Josep, The expanding role of immunotherapy, 10.1016/j.ctrv.2017.01.008
  17. Shang N, Figini M, Shangguan J, Wang B, Sun C, Pan L, et al. Dendritic cells based immunotherapy. Am J Cancer Res. 2017;7(10):2091–102.
  18. Obara Wataru, Kanehira Mitsugu, Katagiri Toyomasa, Kato Renpei, Kato Yoichiro, Takata Ryo, Present status and future perspective of peptide-based vaccine therapy for urological cancer, 10.1111/cas.13506
  19. Toussaint Bertrand, Chauchet Xavier, Wang Yan, Polack Benoit, Gouëllec Audrey Le, Live-attenuated bacteria as a cancer vaccine vector, 10.1586/14760584.2013.836914
  20. Russell Stephen J., Barber Glen N., Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines, 10.1016/j.ccell.2018.03.011
  21. McNamara Megan A., Nair Smita K., Holl Eda K., RNA-Based Vaccines in Cancer Immunotherapy, 10.1155/2015/794528
  22. Herrada Andrés A., Rojas-Colonelli Nicole, González-Figueroa Paula, Roco Jonathan, Oyarce César, Ligtenberg Maarten A, Lladser Alvaro, Harnessing DNA-induced immune responses for improving cancer vaccines, 10.4161/hv.22345
  23. YANKAUCKAS MICHELLE A., MORROW JANE E., PARKER SUEZANNE E., ABAI ANNA, RHODES GARY H., DWARKI VARAVANI J., GROMKOWSKI STANISLAW H., Long-Term Anti-Nucleoprotein Cellular and Humoral Immunity Is Induced by Intramuscular Injection of Plasmid DNA Containing NP Gene, 10.1089/dna.1993.12.771
  24. Lambricht Laure, Lopes Alessandra, Kos Spela, Sersa Gregor, Préat Véronique, Vandermeulen Gaëlle, Clinical potential of electroporation for gene therapy and DNA vaccine delivery, 10.1517/17425247.2016.1121990
  25. Liu Ying, Yan Jing, Santangelo Philip J., Prausnitz Mark R., DNA uptake, intracellular trafficking and gene transfection after ultrasound exposure, 10.1016/j.jconrel.2016.05.013
  26. Miller Douglas L., Pislaru Sorin V., Greenleaf James F., 10.1023/a:1022983907223
  27. van den Berg Joost H., Oosterhuis Koen, Schumacher Ton N. M., Haanen John B. A. G., Bins Adriaan D., Intradermal Vaccination by DNA Tattooing, Methods in Molecular Biology (2014) ISBN:9781493904099 p.131-140, 10.1007/978-1-4939-0410-5_9
  28. Bergmann-Leitner Elke S., Leitner Wolfgang W., Vaccination Using Gene-Gun Technology, Malaria Vaccines (2015) ISBN:9781493928149 p.289-302, 10.1007/978-1-4939-2815-6_22
  29. Li Lei, Petrovsky Nikolai, Molecular mechanisms for enhanced DNA vaccine immunogenicity, 10.1586/14760584.2016.1124762
  30. Ori Daisuke, Murase Motoya, Kawai Taro, Cytosolic nucleic acid sensors and innate immune regulation, 10.1080/08830185.2017.1298749
  31. Tang Choon-Kit, Pietersz Geoffrey A, Intracellular detection and immune signaling pathways of DNA vaccines, 10.1586/erv.09.79
  32. Boyer J, Ugen K, Wang B, Chattergoon M, Tsai A, Merva M, et al. Induction of a TH1 type cellular immune response to the human immunodeficiency type 1 virus by in vivo DNA inoculation. Dev Biol Stand. 1998;92:169–74.
  33. Schirmbeck R, Bohm W, Ando K, Chisari FV, Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol. 1995;69(10):5929–34.
  34. Baghban Rahimi Sanaz, Mohebbi Alireza, Vakilzadeh Gelareh, Biglari Peyvand, Razeghi Jahromi Soodeh, Mohebi Seyed Reza, Shirian Sadegh, Gorji Ali, Ghaemi Amir, Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells, 10.1007/s00705-017-3647-z
  35. Ahrends T., Baba a N., Xiao Y., Yagita H., van Eenennaam H., Borst J., CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination, 10.1158/0008-5472.can-15-3130
  36. Denies Sofie, Cicchelero Laetitia, Polis Ingeborgh, Sanders Niek N., Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs, 10.18632/oncotarget.7265
  37. Lopes Alessandra, Vanvarenberg Kevin, Préat Véronique, Vandermeulen Gaëlle, Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma, 10.1016/j.omtn.2017.07.011
  38. Suschak John J., Williams James A., Schmaljohn Connie S., Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity, 10.1080/21645515.2017.1330236
  39. Jorritsma S.H.T., Gowans E.J., Grubor-Bauk B., Wijesundara D.K., Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines, 10.1016/j.vaccine.2016.09.062
  40. Lambricht Laure, Vanvarenberg Kevin, De Beuckelaer Ans, Van Hoecke Lien, Grooten Johan, Ucakar Bernard, Lipnik Pascale, Sanders Niek N, Lienenklaus Stefan, Préat Véronique, Vandermeulen Gaëlle, Coadministration of a Plasmid Encoding HIV-1 Gag Enhances the Efficacy of Cancer DNA Vaccines, 10.1038/mt.2016.122
  41. Aldous Amanda R., Dong Jesse Z., Personalized neoantigen vaccines: A new approach to cancer immunotherapy, 10.1016/j.bmc.2017.10.021
  42. Rabinovich Gabriel A., Gabrilovich Dmitry, Sotomayor Eduardo M., Immunosuppressive Strategies that are Mediated by Tumor Cells, 10.1146/annurev.immunol.25.022106.141609
  43. Riccardo F, Bolli E, Macagno M, Arigoni M, Cavallo F, Quaglino E. Chimeric DNA vaccines: an effective way to overcome immune tolerance. Curr Top Microbiol Immunol. 2017;405:99–122.
  44. Soong Ruey-Shyang, Trieu Janson, Lee Sung Yong, He Liangmei, Tsai Ya-Chea, Wu T.-C., Hung Chien-Fu, Xenogeneic Human p53 DNA Vaccination by Electroporation Breaks Immune Tolerance to Control Murine Tumors Expressing Mouse p53, 10.1371/journal.pone.0056912
  45. Sioud Mouldy, Sørensen Dag, Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens, 10.1002/immu.200390005
  46. Wei Yuying, Sun Yuanjie, Song Chaojun, Li Haitao, Li Yongming, Zhang Kui, Gong Jiuyu, Liu Fei, Liu Zhijia, August J. T., Jin Boquan, Yang Kun, Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway : DNA vaccine targeting to MHC II pathway, 10.1002/jgm.2624
  47. Grosenbaugh Deborah A., Leard A. Timothy, Bergman Philip J., Klein Mary K., Meleo Karri, Susaneck Steven, Hess Paul R., Jankowski Monika K., Jones Pamela D., Leibman Nicole F., Johnson Maribeth H., Kurzman Ilene D., Wolchok Jedd D., Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor, 10.2460/ajvr.72.12.1631
  48. Quaglino Elena, Riccardo Federica, Macagno Marco, Bandini Silvio, Cojoca Rodica, Ercole Elisabetta, Amici Augusto, Cavallo Federica, Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans, 10.3390/cancers3033225
  49. Almajhdi Fahad N., Senger Tilo, Amer Haitham M., Gissmann Lutz, Öhlschläger Peter, Design of a Highly Effective Therapeutic HPV16 E6/E7-Specific DNA Vaccine: Optimization by Different Ways of Sequence Rearrangements (Shuffling), 10.1371/journal.pone.0113461
  50. Aurisicchio Luigi, Roscilli Giuseppe, Marra Emanuele, Luberto Laura, Mancini Rita, La Monica Nicola, Ciliberto Gennaro, Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen, 10.1089/hum.2014.141
  51. Occhipinti S., Sponton L., Rolla S., Caorsi C., Novarino A., Donadio M., Bustreo S., Satolli M. A., Pecchioni C., Marchini C., Amici A., Cavallo F., Cappello P., Pierobon D., Novelli F., Giovarelli M., Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients, 10.1158/1078-0432.ccr-13-2663
  52. Ruffini Pier, Os Audun, Dolcetti Riccardo, Tjønnfjord Geir E, Munthe Ludvig A, Bogen Bjarne, Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice, 10.1186/1479-5876-12-207
  53. Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun. 2009;9:5.
  54. Yuan Jianda, Ku Geoffrey Y, Adamow Matthew, Mu Zhenyu, Tandon Sapna, Hannaman Drew, Chapman Paul, Schwartz Gary, Carvajal Richard, Panageas Katherine S, Houghton Alan N, Wolchok Jedd D, Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma, 10.1186/2051-1426-1-20
  55. Brennick Cory A, George Mariam M, Corwin William L, Srivastava Pramod K, Ebrahimi-Nik Hakimeh, Neoepitopes as cancer immunotherapy targets: key challenges and opportunities, 10.2217/imt-2016-0146
  56. Aurisicchio Luigi, Pallocca Matteo, Ciliberto Gennaro, Palombo Fabio, The perfect personalized cancer therapy: cancer vaccines against neoantigens, 10.1186/s13046-018-0751-1
  57. Keskin Derin B., Anandappa Annabelle J., Sun Jing, Tirosh Itay, Mathewson Nathan D., Li Shuqiang, Oliveira Giacomo, Giobbie-Hurder Anita, Felt Kristen, Gjini Evisa, Shukla Sachet A., Hu Zhuting, Li Letitia, Le Phuong M., Allesøe Rosa L., Richman Alyssa R., Kowalczyk Monika S., Abdelrahman Sara, Geduldig Jack E., Charbonneau Sarah, Pelton Kristine, Iorgulescu J. Bryan, Elagina Liudmila, Zhang Wandi, Olive Oriol, McCluskey Christine, Olsen Lars R., Stevens Jonathan, Lane William J., Salazar Andres M., Daley Heather, Wen Patrick Y., Chiocca E. Antonio, Harden Maegan, Lennon Niall J., Gabriel Stacey, Getz Gad, Lander Eric S., Regev Aviv, Ritz Jerome, Neuberg Donna, Rodig Scott J., Ligon Keith L., Suvà Mario L., Wucherpfennig Kai W., Hacohen Nir, Fritsch Edward F., Livak Kenneth J., Ott Patrick A., Wu Catherine J., Reardon David A., Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial, 10.1038/s41586-018-0792-9
  58. Sahin Ugur, Türeci Özlem, Personalized vaccines for cancer immunotherapy, 10.1126/science.aar7112
  59. Schumacher Ton N., Schreiber Robert D., Neoantigens in cancer immunotherapy, 10.1126/science.aaa4971
  60. Duperret Elizabeth K., Perales-Puchalt Alfredo, Stoltz Regina, G.H. Hiranjith, Mandloi Nitin, Barlow James, Chaudhuri Amitabha, Sardesai Niranjan Y., Weiner David B., A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge, 10.1158/2326-6066.cir-18-0283
  61. Vasquez Marcos, Tenesaca Shirley, Berraondo Pedro, New trends in antitumor vaccines in melanoma, 10.21037/atm.2017.09.09
  62. Kreiter Sebastian, Vormehr Mathias, van de Roemer Niels, Diken Mustafa, Löwer Martin, Diekmann Jan, Boegel Sebastian, Schrörs Barbara, Vascotto Fulvia, Castle John C., Tadmor Arbel D., Schoenberger Stephen P., Huber Christoph, Türeci Özlem, Sahin Ugur, Mutant MHC class II epitopes drive therapeutic immune responses to cancer, 10.1038/nature14426
  63. Lee Chung-Han, Yelensky Roman, Jooss Karin, Chan Timothy A., Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different, 10.1016/j.it.2018.04.005
  64. Hundal Jasreet, Carreno Beatriz M., Petti Allegra A., Linette Gerald P., Griffith Obi L., Mardis Elaine R., Griffith Malachi, pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens, 10.1186/s13073-016-0264-5
  65. Hellmann Matthew D., Snyder Alexandra, Making It Personal: Neoantigen Vaccines in Metastatic Melanoma, 10.1016/j.immuni.2017.08.001
  66. Sahin Ugur, Derhovanessian Evelyna, Miller Matthias, Kloke Björn-Philipp, Simon Petra, Löwer Martin, Bukur Valesca, Tadmor Arbel D., Luxemburger Ulrich, Schrörs Barbara, Omokoko Tana, Vormehr Mathias, Albrecht Christian, Paruzynski Anna, Kuhn Andreas N., Buck Janina, Heesch Sandra, Schreeb Katharina H., Müller Felicitas, Ortseifer Inga, Vogler Isabel, Godehardt Eva, Attig Sebastian, Rae Richard, Breitkreuz Andrea, Tolliver Claudia, Suchan Martin, Martic Goran, Hohberger Alexander, Sorn Patrick, Diekmann Jan, Ciesla Janko, Waksmann Olga, Brück Alexandra-Kemmer, Witt Meike, Zillgen Martina, Rothermel Andree, Kasemann Barbara, Langer David, Bolte Stefanie, Diken Mustafa, Kreiter Sebastian, Nemecek Romina, Gebhardt Christoffer, Grabbe Stephan, Höller Christoph, Utikal Jochen, Huber Christoph, Loquai Carmen, Türeci Özlem, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, 10.1038/nature23003
  67. Marusyk Andriy, Almendro Vanessa, Polyak Kornelia, Intra-tumour heterogeneity: a looking glass for cancer?, 10.1038/nrc3261
  68. Duperret Elizabeth K., Perales-Puchalt Alfredo, Stoltz Regina, G.H. Hiranjith, Mandloi Nitin, Barlow James, Chaudhuri Amitabha, Sardesai Niranjan Y., Weiner David B., A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge, 10.1158/2326-6066.cir-18-0283
  69. Bae J, Prabhala R, Voskertchian A, Brown A, Maguire C, Richardson P, Dranoff G, Anderson K C, Munshi N C, A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients, 10.1038/leu.2014.159
  70. Bei Roberto, Scardino Antonio, TAA Polyepitope DNA-Based Vaccines: A Potential Tool for Cancer Therapy, 10.1155/2010/102758
  71. Tan Amabel C. L., La Gruta Nicole L., Zeng Weiguang, Jackson David C., Precursor Frequency and Competition Dictate the HLA-A2–Restricted CD8+ T Cell Responses to Influenza A Infection and Vaccination in HLA-A2.1 Transgenic Mice, 10.4049/jimmunol.1100664
  72. Palmowski Michael, Salio Mariolina, Dunbar Rod P., Cerundolo Vincenzo, The use of HLA class I tetramers to design a vaccination strategy for melanoma patients, 10.1034/j.1600-065x.2002.18814.x
  73. Durántez M., López-Vázquez A. B., de Cerio A. L.-D., Huarte E., Casares N., Prieto J., Borrás-Cuesta F., Lasarte J. J., Sarobe P., Induction of Multiepitopic and Long-Lasting Immune Responses Against Tumour Antigens by Immunization with Peptides, DNA and Recombinant Adenoviruses Expressing Minigenes, 10.1111/j.1365-3083.2008.02202.x
  74. Galaine Jeanne, Borg Christophe, Godet Yann, Adotévi Olivier, Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine, 10.3390/vaccines3030490
  75. Protti M. P., Monte L. D., Lullo G. D., Tumor antigen-specific CD4+T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies : CD4+T cells in tumor immunity, 10.1111/tan.12329
  76. Efremova Mirjana, Finotello Francesca, Rieder Dietmar, Trajanoski Zlatko, Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy, 10.3389/fimmu.2017.01679
  77. Doan Tracy, Herd Karen, Ramshaw Ian, Thomson Scott, Tindle Robert W., A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour, 10.1007/s00262-004-0544-6
  78. Lund Lars H, Andersson Karolina, Zuber Bartek, Karlsson Anneli, Engström Gunnel, Hinkula Jorma, Wahren Britta, Winberg Gösta, Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system, 10.1038/sj.cgt.7700574
  79. Lu Yong, Ouyang Kedong, Fang Jing, Zhang Huiyong, Wu Guojun, Ma Yanjun, Zhang Yu, Hu Xiangbing, Jin Liang, Cao Rongyue, Fan Hao, Li Taiming, Liu Jingjing, Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope, 10.1016/j.vaccine.2009.06.089
  80. Scardino Antonio, Alimandi Maurizio, Correale Pierpaolo, Smith Steven G., Bei Roberto, Firat Hüseyin, Cusi Maria Grazia, Faure Olivier, Graf-Dubois Stephanie, Cencioni Giulia, Marrocco Jordan, Chouaib Salem, Lemonnier François A., Jackson Andrew Michael, Kosmatopoulos Kostas, A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge, 10.1158/0008-5472.can-06-3998
  81. Wu A, Zeng Q, Kang T H, Peng S, Roosinovich E, Pai S I, Hung C-F, Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer, 10.1038/gt.2010.151
  82. Cho Hyun-Il, Celis Esteban, Design of immunogenic and effective multi-epitope DNA vaccines for melanoma, 10.1007/s00262-011-1110-7
  83. Hung Chien-Fu, Tsai Ya-Chea, He Liangmei, Wu T-C, DNA Vaccines Encoding Ii-PADRE Generates Potent PADRE-specific CD4+ T-Cell Immune Responses and Enhances Vaccine Potency, 10.1038/sj.mt.6300121
  84. Park Jae Yeo, Jin Dong-Hoon, Lee Chang-Min, Jang Min Ja, Lee Sun Young, Shin Hyo Seon, Chung Yoon Hee, Kim Kyung Yong, Kim Sung Su, Lee Won Bok, Shin Yong Kyoo, Lee Wang Jae, Park Yeong-Min, Kim Daejin, CD4+ TH1 Cells Generated by Ii-PADRE DNA at Prime Phase Are Important to Induce Effectors and Memory CD8+ T Cells : , 10.1097/cji.0b013e3181d75cef
  85. Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun. 2013;13:15.
  86. Khalili Saeed, Rahbar Mohammad Reza, Dezfulian Mohammad Haj, Jahangiri Abolfazl, In silico analyses of Wilms׳ tumor protein to designing a novel multi-epitope DNA vaccine against cancer, 10.1016/j.jtbi.2015.04.026
  87. Wu Yahong, Zhai Wenjie, Sun Meng, Zou Zhe, Zhou Xiuman, Li Guodong, Yan Zhongyi, Qi Yuanming, Gao Yanfeng, A Novel Recombinant Multi-Epitope Vaccine Could Induce Specific Cytotoxic T Lymphocyte Response In Vitro and In Vivo, 10.2174/0929866524666170419152700
  88. Ahrends T., Baba a N., Xiao Y., Yagita H., van Eenennaam H., Borst J., CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination, 10.1158/0008-5472.can-15-3130
  89. CHEN RUILING, WANG SHENGCHAO, YAO YUNLIANG, ZHOU YUN, ZHANG CHONG, FANG JIE, ZHANG DAYONG, ZHANG LIHUANG, PAN JIANPING, Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide, 10.3892/or.2015.3820
  90. Villarreal Daniel O, Wise Megan C, Siefert Rebekah J, Yan Jian, Wood Laurence M, Weiner David B, Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity, 10.1038/mt.2015.120
  91. Vandermeulen Gaëlle, Vanvarenberg Kevin, De Beuckelaer Ans, De Koker Stefaan, Lambricht Laure, Uyttenhove Catherine, Reschner Anca, Vanderplasschen Alain, Grooten Johan, Préat Véronique, The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation, 10.1016/j.vaccine.2015.05.005
  92. Melero Ignacio, Berman David M., Aznar M. Angela, Korman Alan J., Gracia José Luis Pérez, Haanen John, Evolving synergistic combinations of targeted immunotherapies to combat cancer, 10.1038/nrc3973
  93. McDermott David F., Regan Meredith M., Clark Joseph I., Flaherty Lawrence E., Weiss Geoffery R., Logan Theodore F., Kirkwood John M., Gordon Michael S., Sosman Jeffrey A., Ernstoff Marc S., Tretter Christopher P.G., Urba Walter J., Smith John W., Margolin Kim A., Mier James W., Gollob Jared A., Dutcher Janice P., Atkins Michael B., Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma, 10.1200/jco.2005.03.206
  94. Gupta S, Termini JM, Rivas Y, Otero M, Raffa FN, Bhat V, et al. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine. 2015;33(38):4798–806.
  95. Diniz M. O., Sales N. S., Silva J. R., Ferreira L. C. S., Protection against HPV-16-Associated Tumors Requires the Activation of CD8+ Effector Memory T Cells and the Control of Myeloid-Derived Suppressor Cells, 10.1158/1535-7163.mct-15-0742
  96. Cunha Lucas Leite, Marcello Marjory Alana, Rocha-Santos Vinicius, Ward Laura Sterian, Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way, 10.1530/erc-17-0222
  97. Achkar Tala, Tarhini Ahmad A., The use of immunotherapy in the treatment of melanoma, 10.1186/s13045-017-0458-3
  98. Puzanov Igor, Milhem Mohammed M., Andtbacka Robert Hans Ingemar, Minor David R., Hamid Omid, Li Ai, Chastain Michael, Gorski Kevin, Anderson Abraham, Vanderwalde Ari M., Chou Jeffrey, Kaufman Howard, Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma., 10.1200/jco.2014.32.15_suppl.9029
  99. Sandin Linda C, Eriksson Fredrik, Ellmark Peter, Loskog Angelica SI, Tötterman Thomas H, Mangsbo Sara M, Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo, 10.4161/onci.27614
  100. Gao Y, Whitaker-Dowling P, Griffin J A, Barmada M A, Bergman I, Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors, 10.1038/cgt.2008.55
  101. Furness Andrew JS, Quezada Sergio A, Peggs Karl S, Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?, 10.2217/imt-2016-0064
  102. Snyder Alexandra, Makarov Vladimir, Merghoub Taha, Yuan Jianda, Zaretsky Jesse M., Desrichard Alexis, Walsh Logan A., Postow Michael A., Wong Phillip, Ho Teresa S., Hollmann Travis J., Bruggeman Cameron, Kannan Kasthuri, Li Yanyun, Elipenahli Ceyhan, Liu Cailian, Harbison Christopher T., Wang Lisu, Ribas Antoni, Wolchok Jedd D., Chan Timothy A., Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, 10.1056/nejmoa1406498
  103. Rizvi Naiyer A., Hellmann Matthew D., Snyder Alexandra, Kvistborg Pia, Makarov Vladimir, Havel Jonathan J., Lee William, Yuan Jianda, Wong Phillip, Ho Teresa S., Miller Martin L., Rekhtman Natasha, Moreira Andre L., Ibrahim Fawzia, Bruggeman Cameron, Gasmi Billel, Zappasodi Roberta, Maeda Yuka, Sander Chris, Garon Edward B., Merghoub Taha, Wolchok Jedd D., Schumacher Ton N., Chan Timothy A., Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer, 10.1126/science.aaa1348
  104. Maleki Vareki Saman, High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors, 10.1186/s40425-018-0479-7
  105. Hu Zishuo I., Ho Alice Y., McArthur Heather L., Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer, 10.1016/j.ijrobp.2017.05.029
  106. Messenheimer David J., Jensen Shawn M., Afentoulis Michael E., Wegmann Keith W., Feng Zipei, Friedman David J., Gough Michael J., Urba Walter J., Fox Bernard A., Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40, 10.1158/1078-0432.ccr-16-2677
  107. Kleinovink Jan Willem, Fransen Marieke F., Löwik Clemens W., Ossendorp Ferry, Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8 + T Cells, 10.1158/2326-6066.cir-17-0055
  108. Xue Wei, Metheringham Rachael L., Brentville Victoria A., Gunn Barbara, Symonds Peter, Yagita Hideo, Ramage Judith M., Durrant Lindy G., SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade, 10.1080/2162402x.2016.1169353
  109. Lopes Alessandra, Vanvarenberg Kevin, Kos Špela, Lucas Sophie, Colau Didier, Van den Eynde Benoît, Préat Véronique, Vandermeulen Gaëlle, Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma, 10.1038/s41598-018-33933-7
  110. Masucci Giuseppe V., Cesano Alessandra, Hawtin Rachael, Janetzki Sylvia, Zhang Jenny, Kirsch Ilan, Dobbin Kevin K., Alvarez John, Robbins Paul B., Selvan Senthamil R., Streicher Howard Z., Butterfield Lisa H., Thurin Magdalena, Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation, 10.1186/s40425-016-0178-1
  111. Chabanon R. M., Pedrero M., Lefebvre C., Marabelle A., Soria J.-C., Postel-Vinay S., Mutational Landscape and Sensitivity to Immune Checkpoint Blockers, 10.1158/1078-0432.ccr-16-0903
  112. Sasso Maria Stella, Lollo Giovanna, Pitorre Marion, Solito Samantha, Pinton Laura, Valpione Sara, Bastiat Guillaume, Mandruzzato Susanna, Bronte Vincenzo, Marigo Ilaria, Benoit Jean-Pierre, Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy, 10.1016/j.biomaterials.2016.04.010
  113. Sevko Alexandra, Kremer Veronika, Falk Christine, Umansky Ludmila, Shurin Michael R., Shurin Galina V., Umansky Viktor, Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice, 10.3109/1547691x.2012.655343
  114. Wu Junjie, Waxman David J, Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+T-cell responses and immune memory, 10.1080/2162402x.2015.1005521
  115. Xia Qiu, Geng Fei, Zhang Fang-Fang, Liu Chen-Lu, Xu Ping, Lu Zhen-Zhen, Xie Yu, Sun Bo, Wu Hui, Yu Bin, Kong Wei, Yu Xiang-Hui, Zhang Hai-Hong, Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma, 10.1080/08923973.2016.1269337
  116. Pfirschke Christina, Engblom Camilla, Rickelt Steffen, Cortez-Retamozo Virna, Garris Christopher, Pucci Ferdinando, Yamazaki Takahiro, Poirier-Colame Vichnou, Newton Andita, Redouane Younes, Lin Yi-Jang, Wojtkiewicz Gregory, Iwamoto Yoshiko, Mino-Kenudson Mari, Huynh Tiffany G., Hynes Richard O., Freeman Gordon J., Kroemer Guido, Zitvogel Laurence, Weissleder Ralph, Pittet Mikael J., Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy, 10.1016/j.immuni.2015.11.024
  117. Finke J. H., Rini B., Ireland J., Rayman P., Richmond A., Golshayan A., Wood L., Elson P., Garcia J., Dreicer R., Bukowski R., Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients, 10.1158/1078-0432.ccr-07-5212
  118. Immune Consequences of Tyrosine Kinase Inhibitors that Synergize with Cancer Immunotherapy, 10.14800/ccm.677
  119. Generali D., Bates G., Berruti A., Brizzi M. P., Campo L., Bonardi S., Bersiga A., Allevi G., Milani M., Aguggini S., Dogliotti L., Banham A. H., Harris A. L., Bottini A., Fox S. B., Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients, 10.1158/1078-0432.ccr-08-1507
  120. Ferrara TA, Hodge JW, Gulley JL. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther. 2009;11(1):37–42.
  121. Chakraborty Mala, Abrams Scott I., Coleman C. Norman, Camphausen Kevin, Schlom Jeffrey, Hodge James W., External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing, 10.1158/0008-5472.can-04-0073
  122. ClinicalTrials.gov . Accessed 21/02/2019 [21/02/2019]. Available from: https://clinicaltrials.gov/ .
  123. Trimble Cornelia L, Morrow Matthew P, Kraynyak Kimberly A, Shen Xuefei, Dallas Michael, Yan Jian, Edwards Lance, Parker R Lamar, Denny Lynette, Giffear Mary, Brown Ami Shah, Marcozzi-Pierce Kathleen, Shah Divya, Slager Anna M, Sylvester Albert J, Khan Amir, Broderick Kate E, Juba Robert J, Herring Timothy A, Boyer Jean, Lee Jessica, Sardesai Niranjan Y, Weiner David B, Bagarazzi Mark L, Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial, 10.1016/s0140-6736(15)00239-1
  124. Kim Tae Jin, Jin Hyun-Tak, Hur Soo-Young, Yang Hyun Gul, Seo Yong Bok, Hong Sung Ran, Lee Chang-Woo, Kim Suhyeon, Woo Jung-Won, Park Ki Seok, Hwang Youn-Young, Park Jaehan, Lee In-Ho, Lim Kyung-Taek, Lee Ki-Heon, Jeong Mi Seon, Surh Charles D., Suh You Suk, Park Jong Sup, Sung Young Chul, Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients, 10.1038/ncomms6317
  125. Tiriveedhi V., Tucker N., Herndon J., Li L., Sturmoski M., Ellis M., Ma C., Naughton M., Lockhart A. C., Gao F., Fleming T., Goedegebuure P., Mohanakumar T., Gillanders W. E., Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer, 10.1158/1078-0432.ccr-14-0059
  126. Tiriveedhi Venkataswarup, Fleming Timothy P., Goedegebuure Peter S., Naughton Michael, Ma Cynthia, Lockhart Craig, Gao Feng, Gillanders William E., Mohanakumar T., Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells, 10.1007/s10549-012-2110-9
  127. Soysal S. D., Muenst S., Kan-Mitchell J., Huarte E., Zhang X., Wilkinson-Ryan I., Fleming T., Tiriveedhi V., Mohanakumar T., Li L., Herndon J., Oertli D., Goedegebuure S. P., Gillanders W. E., Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes, 10.1007/s10549-014-3129-x
  128. Eriksson Fredrik, Tötterman Thomas, Maltais Anna-Karin, Pisa Pavel, Yachnin Jeffrey, DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer, 10.1016/j.vaccine.2013.06.063
  129. McCann KJ, Godeseth R, Chudley L, Mander A, Di Genova G, Lloyd-Evans P, et al. Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunol Immunother. 2015;64(8):1021–32.
  130. Ottensmeier C, Bowers M, Hamid D, Maishman T, Regan S, Wood W, et al. Wilms’ tumour antigen 1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a phase II non-randomised clinical trial (WIN). Efficacy and mechanism evaluation. Southampton: NIHR Journals Library; 2016.
  131. Niethammer Andreas G, Lubenau Heinz, Mikus Gerd, Knebel Philipp, Hohmann Nicolas, Leowardi Christine, Beckhove Philipp, Akhisaroglu Mustafa, Ge Yingzi, Springer Marco, Grenacher Lars, Buchler Markus W, Koch Moritz, Weitz Jürgen, Haefeli Walter E, Schmitz-Winnenthal Friedrich H, Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer, 10.1186/1471-2407-12-361
  132. Diaz-Montero Claudia Marcela, Chiappori Alberto, Aurisicchio Luigi, Bagchi Ansuman, Clark Jason, Dubey Sheri, Fridman Arthur, Fabregas Jesus C, Marshall John, Scarselli Elisa, La Monica Nicola, Ciliberto Gennaro, Montero Alberto J, Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors, 10.1186/1479-5876-11-62
  133. Cheever M. A., Allison J. P., Ferris A. S., Finn O. J., Hastings B. M., Hecht T. T., Mellman I., Prindiville S. A., Viner J. L., Weiner L. M., Matrisian L. M., The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research, 10.1158/1078-0432.ccr-09-0737
  134. Aurisicchio Luigi, Salvatori Erika, Lione Lucia, Bandini Silvio, Pallocca Matteo, Maggio Roberta, Fanciulli Maurizio, De Nicola Francesca, Goeman Frauke, Ciliberto Gennaro, Conforti Antonella, Luberto Laura, Palombo Fabio, Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth, 10.1186/s13046-019-1084-4
  135. Overgaard Nana H, Fan Timothy M, Schachtschneider Kyle M, Principe Daniel R, Schook Lawrence B, Jungersen Gregers, Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research, 10.1093/ilar/ily014
  136. Gableh Fateme, Saeidi Mohsen, Hemati Shaghayegh, Hamdi Kasra, Soleimanjahi Hoorieh, Gorji Ali, Ghaemi Amir, Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine, 10.1186/s12929-016-0238-3
  137. Allen Alex, Wang Chuan, Caproni Lisa J., Sugiyarto Gessa, Harden Elena, Douglas Leon R., Duriez Patrick J., Karbowniczek Kinga, Extance Jon, Rothwell Paul J., Orefo Ifeayinwa, Tite John P., Stevenson Freda K., Ottensmeier Christian H., Savelyeva Natalia, Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model, 10.1007/s00262-017-2111-y
  138. Jiang Wenbo, Wang Shuangshuang, Chen Honglin, Ren Huanhuan, Huang Xun, Wang Guiqin, Chen Ze, Chen Ling, Chen Zhiwei, Zhou Paul, A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses, 10.1128/jvi.02052-16
  139. Longo Dario Livio, Dastrù Walter, Consolino Lorena, Espak Miklos, Arigoni Maddalena, Cavallo Federica, Aime Silvio, Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment, 10.1016/j.mri.2015.03.005
  140. Nguyen-Hoai T, Pham-Duc M, Gries M, Dörken B, Pezzutto A, Westermann J, CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model, 10.1038/cgt.2016.9
  141. Xia Qiu, Zhang Fang-Fang, Geng Fei, Liu Chen-Lu, Xu Ping, Lu Zhen-Zhen, Yu Bin, Wu Hui, Wu Jia-Xin, Zhang Hai-Hong, Kong Wei, Yu Xiang-Hui, Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model, 10.1007/s00262-016-1827-4
  142. Witt Kristina, Ligtenberg Maarten A., Conti Laura, Lanzardo Stefania, Ruiu Roberto, Wallmann Tatjana, Tufvesson-Stiller Helena, Chambers Benedict J., Rolny Charlotte, Lladser Alvaro, Lundqvist Andreas, Cavallo Federica, Kiessling Rolf, Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma, 10.1158/2326-6066.cir-17-0572
  143. Zhong Boya, Ma Guangyu, Sato Ayako, Shimozato Osamu, Liu Hongdan, Li Quanhai, Shingyoji Masato, Tada Yuji, Tatsumi Koichiro, Shimada Hideaki, Hiroshima Kenzo, Tagawa Masatoshi, Fas Ligand DNA Enhances a Vaccination Effect by Coadministered DNA Encoding a Tumor Antigen through Augmenting Production of Antibody against the Tumor Antigen, 10.1155/2015/743828
  144. Danishmalik Sayyed Nilofar, Sin Jeong-Im, Therapeutic Tumor Control of HER2 DNA Vaccines Is Achieved by an Alteration of Tumor Cells and Tumor Microenvironment by Gemcitabine and Anti-Gr-1 Ab Treatment in a HER2-Expressing Tumor Model, 10.1089/dna.2017.3810
  145. Liu C., Xie Y., Sun B., Geng F., Zhang F., Guo Q., Wu H., Yu B., Wu J., Yu X., Kong W., Zhang H., MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model, 10.1111/sji.12633
  146. Son Hye-Youn, Apostolopoulos Vasso, Chung June-Key, Kim Chul-Woo, Park Ji-Ung, Protective efficacy of a plasmid DNA vaccine against transgene-specific tumors by Th1 cellular immune responses after intradermal injection, 10.1016/j.cellimm.2018.04.003
  147. Yin Xiaotao, Wang Wei, Zhu Xiaoming, Wang Yu, Wu Shuai, Wang Zicheng, Wang Lin, Du Zhiyan, Gao Jiangping, Yu Jiyun, Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis, 10.1016/j.bbrc.2015.08.003
  148. Gao Fu-Sheng, Zhan Yu-Tao, Wang Xu-Dong, Zhang Chuan, Enhancement of anti-tumor effect of plasmid DNA-carrying MUC1 by the adjuvanticity of FLT3L in mouse model, 10.1080/08923973.2018.1498099
  149. Yu Shaojuan, Wang Fuli, Fan Li, Wei Yuying, Li Haitao, Sun Yuanjie, Yang Angang, Jin Boquan, Song Chaojun, Yang Kun, BAP31, a promising target for the immunotherapy of malignant melanomas, 10.1186/s13046-015-0153-6
  150. Mählmann Kathrin, Feige Karsten, Juhls Christiane, Endmann Anne, Schuberth Hans-Joachim, Oswald Detlef, Hellige Maren, Doherr Marcus, Cavalleri Jessika-MV, Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma, 10.1186/s12917-015-0422-9
  151. Ahn Euri, Kim Ha, Han Kyusun Torque, Sin Jeong-Im, A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model, 10.1016/j.canlet.2014.10.019
  152. Rekoske B. T., Smith H. A., Olson B. M., Maricque B. B., McNeel D. G., PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization, 10.1158/2326-6066.cir-14-0206
  153. Zhao Youguang, Wei Zhitao, Yang Hang, Li Xiaowei, Wang Qiwu, Wang Liang, Li Shadan, Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4), 10.1016/j.biopha.2017.03.015
Bibliographic reference Lopes, Alessandra ; Vandermeulen, Gaëlle ; Préat, Véronique. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives.. In: Journal of experimental & clinical cancer research : CR, Vol. 38, no.1, p. 146 (2019)
Permanent URL http://hdl.handle.net/2078.1/217056